At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 287 enrolled
Drug / intervention
armodafinil +3 moredrug
Likely dose
armodafinil 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia
In Brief
A Phase 2 clinical trial evaluating armodafinil and placebo for Schizophrenia. Completed, enrolled 287 participants across 39 sites.
Detailed Summary
The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionMar 2010
Study CompletionMay 2010
TodayJul 2026
First PostedOct 15, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.7 years ago
Interventions
armodafinildrug
150 mg/day armodafinil
placebodrug
placebo
armodafinildrug
200 mg/day armodafinil
armodafinildrug
250 mg/day armodafinil